Clinical trials: Intestinal Motility
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Functional Gastrointestinal Disorders
Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function
Several studies have been done on the efficacy of the herbal medicine Iberogast. In this study researcher want to learn more about the time needed for Iberogast to start to work after the patient took the drug.
- Trial name
- NCT04059783
- Testing
- STW5 (Iberogast®, BAY98-7411)
- Where
- Germany
- Volunteers
- 272 people
- Sponsor
- Bayer
Gastrointestinal Dysmotility
Ulimorelin Study of Efficacy and Safety (ULISES 008)
Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection
- Trial name
- NCT01296620
- Testing
- Ulimorelin Intravenously (IV), Ulimorelin Invtravenously (IV), 5% dextrose in water
- Where
- 50 sites in United States, Bulgaria and 4 more
- Volunteers
- 330 people
- Sponsor
- Tranzyme, Inc.
Refractory Reflux Esophagitis
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.
- Trial name
- NCT00770913
- Testing
- E3810
- Where
- 54 sites in Japan
- Volunteers
- 337 people
- Sponsor
- Eisai Co., Ltd.
Reflux Esophagitis, Gastroesophageal Reflux
A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis
A phase 2, randomized, double-blind, double-dummy, positive drug parallel controlled, multicenter trial to evaluate efficacy and safety of within 8 weeks (including 8 weeks) treatment of Anaprazole 40mg QD, 60mg QD compared with…
- Conditions
- Reflux Esophagitis, Gastroesophageal Reflux, Esophagitis, Esophageal Motility Disorders
- Trial name
- NCT05604261
- Testing
- Anaprazole sodium 40 mg, Anaprazole sodium 60 mg, Rabeprazole sodium 20 mg
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Reflux Esophagitis
The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.
- Trial name
- NCT01860482
- Testing
- Newrabell® Tablet 10mg
- Where
- 2 sites in South Korea
- Volunteers
- 39 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Dyspepsia
The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.
"Functional dyspepsia" has been defined loosely as "pain or discomfort centered in the upper abdomen." The symptoms can also include fullness, early satiety, bloating, belching, nausea, retching and vomiting.
- Trial name
- NCT00303264
- Testing
- dexloxiglumide, Nexium (esomeprazole)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Forest Laboratories
Reflux Esophagitis
Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis
The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.
- Trial name
- NCT04531475
- Testing
- X842, Lansoprazole
- Where
- 16 sites in China
- Volunteers
- 90 people
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Constipation
Probiotics for Alleviating Chronic Constipation in Adults
To investigate the clinical effects of probiotics in relieving intestinal motility and chronic constipation through regulating gut microbiota.
- Trial name
- NCT07152795
- Testing
- Probiotic
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Gastroparesis
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
This study is a randomized, double-blind, placebo controlled trial designed to confirm the symptomatic effects of camicinal treatment vs. placebo, on gastroparesis symptoms in type 1 and 2 diabetic subjects with gastroparesis.
- Trial name
- NCT02210000
- Testing
- Camicinal
- Where
- 34 sites in United States
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Gastroesophageal Reflux
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the patients with mild reflux oesophagitis.
- Trial name
- NCT00229424
- Testing
- Lafutidine, Famotidine
- Where
- Japan
- Volunteers
- 325 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome
Nexium Capsules Clinical Experience Investigation
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for "gastric ulcer", "duodenal…
- Trial name
- NCT01434485
- Where
- 47 sites in Japan
- Volunteers
- 3,691 people
- Sponsor
- AstraZeneca
Gastroparesis
Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance
The aims of MOT112571 are to assess the pharmacodynamic effects, safety, tolerability, pharmacokinetics, and potential therapeutic benefit of single doses of GSK962040 in critically ill patients with delayed gastric emptying and…
- Trial name
- NCT01039805
- Testing
- GSK962040 (50 mg), GSK962040 (75 mg)
- Where
- Australia
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome, Gallstone Disease
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in…
- Conditions
- Irritable Bowel Syndrome, Gallstone Disease, GERD, Biliary Dyskinesia
- Trial name
- NCT07421011
- Testing
- Trimedat®
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
GERD
Electronic Health Record (EHR)-Based Intervention for Gastroesophageal Reflux Disease (GERD) and Chronic Non-steroidal Anti-inflammatory Drug (NSAID) Use
The purpose of the study is to examine the impact of augmented, high-quality physician-coordinated care executed via an electronic health record (EHR)-based intervention on quality of care for gastroesophageal reflux disease…
- Trial name
- NCT00691171
- Volunteers
- 5,234 people
- Sponsor
- AstraZeneca